Literature DB >> 15194022

Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study).

Barry J Maron1, Paolo Spirito, Mary J Roman, Mary Paranicas, Peter M Okin, Lyle G Best, Elisa T Lee, Richard B Devereux.   

Abstract

Recognition of the frequency with which hypertrophic cardiomyopathy (HC) occurs in the general population is critical to understanding its demographics and public health implications. However, few data are available for estimating HC prevalence in large populations of different age strata and ethnic or racial groups. The Strong Heart Study is a prospective, population-based epidemiologic survey of cardiovascular disease in residents of 13 geographically diverse American Indian communities. The study population was comprised of 3,501 subjects with echocardiograms performed in 1993 and 1995 to determine the prevalence of HC in middle-aged and older adult populations. Evidence of the HC phenotype was present in 8 previously undiagnosed patients (0.23%; 2 of 1,000) based on a left ventricular (LV) wall thickness >/=15 mm and a nondilated cavity that was not associated with another cardiac disease and was sufficient to produce the magnitude of hypertrophy evident. Ages were 51 to 77 years (mean 64 +/- 9). Four subjects were men and 4 were women, with prevalences by gender of 0.3% (3 of 1,000) and 0.18% (1.8 of 1,000), respectively. Maximum LV thicknesses were 19 to 29 mm (mean 21 +/- 3). Two subjects had mitral valve systolic anterior motion, which was sufficient to produce LV outflow obstruction at rest in 1 patient. Different electrocardiographic abnormalities were present in 5 subjects. In conclusion, clinically unrecognized HC was present in 1:500 of an aging American Indian cohort. This prevalence was similar to that reported in other general populations comprised of younger subjects of other races, offering evidence that HC is a relatively common genetic disease with widespread occurrence within the United States.

Entities:  

Mesh:

Year:  2004        PMID: 15194022     DOI: 10.1016/j.amjcard.2004.03.007

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  19 in total

1.  Structural abnormalities of the left ventricle in hypertrophic cardiomyopathy mutation carriers detectable before the development of hypertrophy.

Authors:  T Germans; A A M Wilde; C J A van Echteld; O Kamp; Y M Pinto; A C van Rossum
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

2.  Hypertrophic cardiomyopathy in children.

Authors:  Arman Arghami; Joseph A Dearani; Sameh M Said; Patrick W O'Leary; Hartzell V Schaff
Journal:  Ann Cardiothorac Surg       Date:  2017-07

Review 3.  Risk stratification in hypertrophic cardiomyopathy.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; S Kachboura
Journal:  Herz       Date:  2018-04-25       Impact factor: 1.443

4.  Baseline Characteristics of the VANISH Cohort.

Authors:  Anna Axelsson Raja; Ling Shi; Sharlene M Day; Mark Russell; Kenneth Zahka; Harry Lever; Steven D Colan; Renee Margossian; E Kevin Hall; Jason Becker; John Lynn Jefferies; Amit R Patel; Lubna Choudhury; Anne M Murphy; Charles Canter; Richard Bach; Matthew Taylor; Luisa Mestroni; Matthew T Wheeler; Lee Benson; Anjali T Owens; Joseph Rossano; Kimberly Y Lin; Elfriede Pahl; Alexandre C Pereira; Henning Bundgaard; Gregory D Lewis; Jose D Vargas; Allison L Cirino; John J V McMurray; Calum A MacRae; Scott D Solomon; E John Orav; Eugene Braunwald; Carolyn Y Ho
Journal:  Circ Heart Fail       Date:  2019-12-09       Impact factor: 8.790

Review 5.  Looking for hypertrophic cardiomyopathy in the community: why is it important?

Authors:  Stefano Nistri; Iacopo Olivotto; Francesca Girolami; Francesca Torricelli; Franco Cecchi; Magdi H Yacoub
Journal:  J Cardiovasc Transl Res       Date:  2009-10-20       Impact factor: 4.132

Review 6.  Distinguishing ventricular septal bulge versus hypertrophic cardiomyopathy in the elderly.

Authors:  Marco Canepa; Iraklis Pozios; Pier Filippo Vianello; Pietro Ameri; Claudio Brunelli; Luigi Ferrucci; Theodore P Abraham
Journal:  Heart       Date:  2016-04-27       Impact factor: 5.994

7.  Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions >55% versus 40% to 55% versus <40%.

Authors:  Kun-Lun He; Daniel Burkhoff; Wen-Xiu Leng; Zhi-Ru Liang; Li Fan; Jie Wang; Mathew S Maurer
Journal:  Am J Cardiol       Date:  2009-03-15       Impact factor: 2.778

8.  Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy.

Authors:  Constantinos O'Mahony; Saidi A Mohiddin; Charles Knight
Journal:  Interv Cardiol       Date:  2014-04

Review 9.  The genetics of cardiomyopathies: what clinicians should know.

Authors:  Rahul Deo; Calum A MacRae
Journal:  Curr Heart Fail Rep       Date:  2007-12

10.  Molecular mechanisms and structural features of cardiomyopathy-causing troponin T mutants in the tropomyosin overlap region.

Authors:  Binnu Gangadharan; Margaret S Sunitha; Souhrid Mukherjee; Ritu Roy Chowdhury; Farah Haque; Narendrakumar Sekar; Ramanathan Sowdhamini; James A Spudich; John A Mercer
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.